Adalimumab Level W Ada,

Test Code

36296

Alias/See Also

1230200764 | LAB3259: Adalimumab Level w/ADA, IBD | QUEST EAP: 36296

CPT Codes
83520, 80145

Preferred Specimen

0.8 mL serum

Patient Preparation

Patient Preparation: Dietary supplements containing biotin may interfere in assays and may skew results to be either falsely high or falsely low. For patients receiving the recommended daily doses of biotin, draw samples at least 8 hours following the last biotin supplementation. For patients on mega-doses of biotin supplements, draw samples at least 72 hours following the last biotin supplementation. Collect immediately before next scheduled dose (trough specimen). Instructions: Draw blood in non-separator gel tube (red top) or separator gel tube (SST). Centrifuge and transfer serum to a labeled plastic transport tube.

Minimum Volume

2 mL

Instructions

Collection instructionsDraw blood in non-separator gel tube (red-top) or separator gel tube (SST). Centrifuge and transfer serum to a labeled plastic transport tube.

Transport containerTransport tube

Transport temperatureRefrigerated (cold packs)

Specimen stabilityRoom temperature: 48 hours
Refrigerated: 8 days
Frozen: 28 days

Rejection criteria: Moderate and gross hemolysis

Transport Container

RED TOP - PLAIN

Transport Temperature

Refrigerated (cold packs)

Specimen Stability

Specimen stabilityRoom temperature: 48 hours
Refrigerated: 8 days
Frozen: 28 days

Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)

Rejection criteria: Moderate and gross hemolysis

Methodology
Chemiluminescent Immunoassay

FDA Status
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

Setup Schedule

Set up: Mon, Tues, Thurs-Sat; Report available: 4-6 days

Reference Range

Adalimumab Level	See Laboratory Report
Adalimumab Ab	<12 AU/mL

Clinical Significance

Adalimumab is a therapeutic monoclonal antibody with the ability to bind to tumor necrosis factor (TNF), an inflammatory cytokine, blocking its action. Adalimumab is indicated for the treatment of Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, and juvenile idiopathic arthritis. It is not significantly immunogenic and only a small percentage of treated patients develop antibodies. However, in these patients, antibodies may be associated with lower trough levels of the drug. Results >12 AU/mL indicate the presence of anti-drug antibody.

Performing Laboratory

Quest Diagnostics Nichols Institute-San Juan Capistrano, CA

33608 Ortega Highway

San Juan Capistrano, CA 92675-2042

Last Updated: October 20, 2026

The CPT Codes provided in this document are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payor being billed. Any Profile/panel component may be ordered separately. Reflex tests are performed at an additional charge.